ACLY and neoplasm: Additionally, the ACLY inhibitor bempedoic acid showed potent anti-tumor activity against all stable cell lines 24 h after the combined treatment, and a significantly lower rate of decrease in IC50 was observed in Lv-MCF7 (Figure S5B).